Summary

Rosuvastatin was found to have no significant benefit in the prevention of cardiovascular death, myocardial infarction, or stroke in symptomatic older patients with systolic heart failure of ischemic etiology in the Controlled Rosuvastatin Multinational [CORONA] trial. However, statin therapy was associated with significantly fewer hospitalizations and significantly decreased levels of low-density lipoprotein compared with placebo.